Kura Oncology (DE:KUR)
FRANKFURT:KUR
KUR Stock Chart & Stats
€7.84
-€0.16(-1.94%)
At close: 4:00 PM EST
€7.84
-€0.16(-1.94%)
Day’s Range― - ―
52-Week Range€4.68 - €10.78
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
€665.69M
Enterprise Value€647.78M
Total Cash (Recent Filing)€667.24M
Total Debt (Recent Filing)€20.46M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Apr 30, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding88,329,760
10 Day Avg. Volume0
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.23
Price to Sales (P/S)13.50
P/FCF Ratio-12.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.02Price Target Upside206.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.05
Revenue Forecast (FY)€102.56M
Bulls Say, Bears Say
Bulls Say
Clinical Data Readouts And Guideline PotentialMultiple upcoming clinical data readouts for ziftomenib and combination programs could validate efficacy, support inclusion in treatment guidelines, and expand prescribing beyond current use.
Funding And Financial FlexibilityA strong cash position combined with anticipated collaboration milestone payments should fund pivotal frontline development through topline results, reducing reliance on equity financing for near-term operations.
Payer Coverage And Early Commercial UptakeBroad private payer policies aligned with the label and initial Komzifti commercial sales signal solid early market uptake and indicate ongoing physician and patient demand.
Bears Say
Competitive PressureManagement notes the market can support multiple competitors and rising competitor share presents increasing pressure on Komzifti's commercial and growth prospects.
Earnings Performance And Dilution RiskReported quarterly and full-year results missed analyst expectations and increases in share count could dilute earnings per share, weighing on near-term valuation.
Payer Restrictions Limiting AccessSeveral large commercial plans are implementing step edits based on pricing that could restrict patient access to Komzifti despite broader coverage elsewhere.
Kura Oncology News
KUR FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was €4.68 and its highest was €10.78 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is €665.69M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Apr 30, 2026 which is in 21 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Mar 05, 2026. The company reported -€0.789 earnings per share for the quarter, missing the consensus estimate of -€0.548 by -€0.241.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.69.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 88,329,760 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -€0.789 in its last earnings report, missing expectations of -€0.548. Following the earnings report the stock price went up 1.366%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in DE:KUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kura Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€24.02 (206.32% Upside)
€24.02 (206.32% Upside)
Blogger Sentiment
Bullish
DE:KUR Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $305.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
56.40%
12-Months-Change
Fundamentals
Return on Equity
-102.59%
Trailing 12-Months
Asset Growth
-29.05%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
KUR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive commercial and clinical story: FDA approval, immediate product shipments, rapid payer coverage (~84% of private payers within 90 days), beneficial payer step edits, patent protection to 2044, robust sales force deployment, and multiple near‑term clinical catalysts across AML and the FTI program. Financially, the company is investing heavily in commercialization and development, which widened operating losses and reduced collaboration revenue year-over-year; cash remains substantial (~$667M) with anticipated milestone support through top-line Phase 3 readout in 2028. Overall, strengths in launch execution, access, patent protection, and a data-rich development plan outweigh near‑term financial pressures and uncertainties around duration of therapy and reliance on milestone timing.View all DE:KUR earnings summariesKUR Stock 12 Month Forecast
Average Price Target
€24.02
▲(206.32% Upside)
Technical Analysis
Oruka Therapeutics
―
Phathom Pharmaceuticals
―
Keros Therapeutics
―
Tyra Bioscience
―
Septerna, Inc.
―
Options Prices
Currently, No data available
---